Kadmon (NYSE:KDMN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Kadmon (NYSE:KDMNGet Rating) in a research report sent to investors on Thursday. The brokerage issued a sell rating on the stock.

Kadmon Stock Performance

NYSE:KDMN opened at $9.50 on Thursday. Kadmon has a 12 month low of $3.19 and a 12 month high of $9.50.

Kadmon Company Profile

(Get Rating)

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Read More

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.